首页> 外文期刊>Stem Cell Research & Therapy >Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease
【24h】

Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease

机译:非肾脏或肾脏来源的基质细胞在实验性慢性肾脏疾病中的治疗潜力

获取原文
           

摘要

Mesenchymal stromal cell (MSC)-based therapy is a promising strategy for preventing the progression of chronic kidney disease (CKD), with the potential to induce tissue regeneration. In search of the best cellular source we compared, in the rat model of adriamycin (ADR) nephropathy, the regenerative potential of human stromal cells of non-renal origin, such as bone marrow (bm) MSCs and umbilical cord (uc) MSCs, with that of newly discovered stromal cells of renal origin, the kidney perivascular cells (kPSCs) known to exhibit tissue-specific properties. The therapeutic effect of repeated infusions of human bmMSCs, ucMSCs, kPSCs (1.5?×?106 cells/rats) or conditioned medium from ucMSCs was studied in athymic rats with ADR-induced nephropathy (7.9?mg/kg). The ability of the three stromal cell populations to engraft the damaged kidney was evaluated by detecting the presence of human nuclear antigenpos cells. Glomerular podocyte loss and endothelial damage, sclerotic lesions and inflammation were assessed at 14 and 28?days. In-vitro experiments with a transwell system were performed to investigate the effects of different stromal cell populations on parietal epithelial cells (PECs) activated or not with albumin or angiotensin II for 24?h. Infusions of non-renal and renal stromal cells resulted in a comparable engraftment into the kidney, in the peritubular areas and around the glomerular structures. All three cell populations limited podocyte loss and glomerular endothelial cell injury, and attenuated the formation of podocyte and PEC bridges. This translated into a reduction of glomerulosclerosis and fibrosis. Human ucMSCs had an anti-inflammatory effect superior to that of the other stromal cells, reducing macrophage infiltration and inducing polarisation towards the M2 macrophage phenotype. Conditioned medium from ucMSCs shared the same renoprotective effects of the cells. Consistent with in-vivo data, bmMSCs and kPSCs, but even more so ucMSCs, limited proliferation, migratory potential and extracellular matrix production of activated PECs, when cultured in a transwell system. Our?data indicate that either non-renal or renal stromal cells induce renal tissue repair, highlighting ucMSCs and their conditioned medium as the most reliable clinical therapeutic tool for CKD patients.
机译:基于间质基质细胞(MSC)的治疗是一种预防慢性肾脏病(CKD)进展的有前途的策略,具有诱导组织再生的潜力。为了寻找最佳的细胞来源,我们在阿霉素(ADR)肾病大鼠模型中比较了非肾脏来源的人基质细胞(如骨髓(bm)MSC和脐带(uc)MSC)的再生潜力,与新近发现的肾源性基质细胞一样,已知的肾血管周围细胞(kPSC)具有组织特异性。在患有ADR的肾病无胸腺大鼠(7.9?mg / kg)中研究了反复输注人bmMSCs,ucMSCs,kPSCs(1.5?×?106细胞/大鼠)或ucMSCs的条件培养基的治疗效果。通过检测人类核抗原阳性细胞的存在,评估了三种基质细胞群移植受损肾脏的能力。在第14天和第28天评估肾小球足细胞丢失和内皮损伤,硬化性病变和炎症。用transwell系统进行了体外实验,以研究不同基质细胞群对白蛋白或血管紧张素II活化或未活化的顶壁上皮细胞(PEC)的作用24?h。输注非肾和肾基质细胞导致相当程度的移植到肾脏,肾小管周围区域和肾小球结构周围。这三个细胞群均限制了足细胞的丢失和肾小球内皮细胞的损伤,并减弱了足细胞和PEC桥的形成。这转化为肾小球硬化和纤维化的减少。人ucMSC具有优于其他基质细胞的抗炎作用,减少了巨噬细胞的浸润并诱导了向M2巨噬细胞表型的极化。来自ucMSC的条件培养基具有相同的细胞肾脏保护作用。与bmMSCs和kPSCs,甚至更多ucMSCs的体内数据一致,当在transwell系统中培养时,激活的PECs的增殖,迁移潜能和细胞外基质产生受到限制。我们的数据表明,非肾或肾基质细胞均可诱导肾组织修复,从而突出ucMSCs及其条件培养基是CKD患者最可靠的临床治疗工具。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号